Olysio’s Stronger-Than-Expected Sales Drive Strong Quarter For J&J
This article was originally published in The Pink Sheet Daily
Executive Summary
Products launched since 2009 have yielded the highest pharmaceutical sales growth among the 10 biggest biopharma companies, more than offsetting a substantial patent cliff. Zytiga and Olysio already have passed the $1 billion sales threshold this year, with Xarelto on pace to do so.
You may also be interested in...
Emerging Markets Earnings Roundup: Johnson & Johnson (Part 1)
Second quarter earnings from Johnson & Johnson shed light on the view on biosimilar launches of Remicade and how the company hopes to streamline its varied arms abroad.
Medivation/Astellas Will Be Ready For Xtandi To Enter Pre-Chemo Prostate Cancer Setting
The oncology drug has been submitted for approval in the larger chemotherapy-naïve patient population and Medivation intends to increase its sales force to support the launch.
FDA Approves Zytiga In Earlier Prostate Cancer Setting
FDA approval of Zytiga in the pre-chemo setting gives the androgen blocker a second prostate cancer indication and another revenue stream – but a short remaining patent life and a significant competitive threat may mitigate the achievement.